

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/023750 A1

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/IB2023/057619
- (22) **International Filing Date:**
27 July 2023 (27.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/393,125 28 July 2022 (28.07.2022) US
- (71) **Applicants:** **ASTRAZENECA UK LIMITED** [GB/GB];
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge CB2 0AA (GB). **DAIICHI SANKYO COM-
PANY, LIMITED** [JP/JP]; 3-5-1, Nihonbashi Honcho,
Chuo-ku, Tokyo 103-8426 (JP).
- (72) **Inventors:** **METTETAL II, Jerome Thomas**; c/o As-
traZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US).
SUNG, Matthew Simon; c/o AstraZeneca Pharmaceu-
ticals LP, 1800 Concord Pike, P.O. Box 15437, Wilming-
ton, Delaware 19850-5437 (US). **PROIA, Theresa Angela**;
c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike,
P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).
JENKINS, Liam Samuel; c/o AstraZeneca UK Limited,
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge CB2 0AA (GB).
- (74) **Agent:** **FAIRBAIRN, Angus Chisholm**; Marks & Clerk
LLP, 15 Fetter Lane, London EC4A 1BW (GB).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** COMBINATION OF ANTIBODY-DRUG CONJUGATE AND BISPECIFIC CHECKPOINT INHIBITOR



(57) **Abstract:** A pharmaceutical product for administration of an antibody-drug conjugate in combination with a bispecific checkpoint inhibitor is provided. The antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an antibody, preferably an anti-TROP2 or anti-HER2 antibody, via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the bispecific checkpoint inhibitor are administered in combination to a subject (Formula I).

WO 2024/023750 A1